



**From:**

Saad Enouri, BVSc, MSc, PhD  
 Research Associate, Canadian gFARAD  
 Ontario Veterinary College  
 senouri@uoguelph.ca  
 Telephone: 519-824-4120 ext. 54984

<b>To:</b> [REDACTED]	<b>Re:</b> Nicarb®, Coxistac, Surmax™ Premix
<b>Telephone:</b> [REDACTED]	<b>Case Id:</b> ON-072220-21811
<b>Fax:</b> [REDACTED]	<b>Date of Response:</b> Jul 22, 2020 2:17:33 PM
<b>Email:</b> [REDACTED]	

**Case Information:**

**Date Submitted** Jul 22, 2020 12:44:36 PM  
**Species** Chickens/Broilers  
**Number of Animals** 19176  
**Location of Animals**  
**Reason for Use** Prophylaxis  
**Drugs Administered**

Drug Trade Name	Generics	Route	Dose	Diseases
Nicarb®	• nicarbazin	Oral - Feed	50 ppm (in feed) Continuously for 14 days	• <b>Alimentary:</b> coccidiosis
Coxistac	• salinomycin	Oral - Feed	50.4 ppm (in feed) Continuously for 14 days	• <b>Alimentary:</b> coccidiosis
Surmax™ Premix	• avilamycin	Oral - Feed	15 ppm (in feed) Continuously for 22 days	• <b>Alimentary:</b> necrotic enteritis - clostridium perfringens

**Response and Recommendation:** 4 days

Nicarbazin is approved for use in chickens (up to 12 weeks of age) for the prevention of coccidiosis up to 200 ppm with no limit to the duration of treatment. When used according to the label directions, the withdrawal time of nicarbazin is 4 days for meat. Salinomycin is approved for broiler chickens for the prevention of coccidiosis at 60 ppm to be fed continuously up to marketing with a zero day withdrawal time. Avilamycin is approved for use in broiler chicken feeds for the

prevention of necrotic enteritis at 15 to 30 ppm for 21 days with a zero day withdrawal time. The CMIB has now included this statement regarding avilamycin: "This livestock feed contains a medically important antibiotic. To reduce the development of antimicrobial resistance and maintain effectiveness, use this antibiotic prudently." Due to concerns regarding antimicrobial resistance, the Veterinary Drugs Directorate will no longer approve antimicrobials for continuous use throughout the production cycle and they strongly discourage extended durations of therapy. As such, we suggest that extended treatments with avilamycin should be avoided whenever possible and if used beyond the approved 21 days, we recommend a withdrawal interval of at least 24 hours. We are not aware of any interaction between these drugs that would require further extension of the withdrawal intervals. Therefore, we recommend following a withdrawal interval of 4 days for this combination.

Therefore, the Canadian gFARAD recommends a withdrawal interval of 4 days, which should be sufficient so that detectable residues are not found. Furthermore, this recommendation for residue avoidance does not address the risks of developing or transmitting antimicrobial resistance from treated animals to other animals or humans following the extralabel use of this antimicrobial. Because the Canadian gFARAD withdrawal recommendation is not an official withdrawal time and is based on data that has not been reviewed nor approved by the Veterinary Drugs Directorate or the Canadian Food Inspection Agency, responsibility for residue violations rests with the attending veterinarian.

To review this request in CgFARAD:

<https://farad.usask.ca/cgfarad/vet/viewRequest?id=21811&langen>